

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE {Carton – 50 ml & 100 ml}**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Cronyxin Injection 50 mg/ml Solution for Injection

**2. STATEMENT OF ACTIVE SUBSTANCES**

Flunixin 50 mg/ml (as Flunixin Meglumine).

**3. PACKAGE SIZE**

50 ml

100 ml

**4. TARGET SPECIES**

Cattle and horses.

**5. INDICATIONS**

**6. ROUTES OF ADMINISTRATION**

Intravenous injection.

**7. WITHDRAWAL PERIODS**

Withdrawal period:

Cattle:

Meat and offal: 8 days.

Milk: 12 hours.

Horses:

Not authorised for use in horses intended for human consumption.

**8. EXPIRY DATE**

Exp. {mm/yyyy}

Once broached, use within 28 days.

Once opened, use by \_\_\_\_\_.

**9. SPECIAL STORAGE PRECAUTIONS**

Do not store above 25 °C.

Keep the container in the outer carton.

**10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”**

Read the package leaflet before use.

**11. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

**12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**13. NAME OF THE MARKETING AUTHORISATION HOLDER**

Bimeda Animal Health Limited

**14. MARKETING AUTHORISATION NUMBERS**

Vm 50146/4011

**15. BATCH NUMBER**

Lot

**PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE {Label – 50 ml & 100 ml}**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Cronyxin Injection 50 mg/ml Solution for Injection

**2. STATEMENT OF ACTIVE SUBSTANCES**

Flunixin 50 mg/ml (as Flunixin Meglumine).

**3. TARGET SPECIES**

Cattle and horses.

**4. ROUTES OF ADMINISTRATION**

Intravenous injection.  
Read the package leaflet before use.

**5. WITHDRAWAL PERIODS**

Withdrawal period:

Cattle:

Meat and offal: 8 days.

Milk: 12 hours.

Horses:

Not authorised for use in horses intended for human consumption.

**6. EXPIRY DATE**

Exp. {mm/yyyy}

Once broached, use within 28 days.

Once opened, use by \_\_\_\_\_.

**7. SPECIAL STORAGE PRECAUTIONS**

Do not store above 25 °C

Keep the container in the outer carton.

**8. NAME OF THE MARKETING AUTHORISATION HOLDER**

Bimeda Animal Health Limited

**9. BATCH NUMBER**

Lot {number}

**PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:**

**PACKAGE LEAFLET**

**1. Name of the veterinary medicinal product**

Cronyxin Injection 50 mg/ml Solution for Injection

**2. Composition**

Each ml contains:

**Active substance:**

Flunixin (as Flunixin meglumine) 50 mg

**Excipients:**

<b>Qualitative composition of excipients and other constituents</b>	<b>Quantitative composition if that information is essential for proper administration of the veterinary medicinal product</b>
Phenol (as preservative)	5.0 mg/ml
Sodium Formaldehyde Sulfoxylate (as antioxidant)	2.2 mg/ml
Disodium Edetate Dihydrate	
Propylene Glycol	
Sodium Hydroxide (for pH adjustment)	
Hydrochloric acid (for pH adjustment)	
Water for injections	

Clear, colourless to light yellow solution, free of foreign matter.

**3. Target species**

Cattle and horses.

**4. Indications for use**

Cattle:

For the control of acute inflammation associated with respiratory disease. It has also been shown to have some benefit in the treatment of experimental acute bovine pulmonary emphysema (Fog Fever). The veterinary medicinal product may be used as adjunctive therapy in the treatment of acute mastitis.

Horses:

For the alleviation of inflammation and pain associated with musculoskeletal disorders. It is also indicated for the alleviation of visceral pain associated with colic.

## **5. Contraindications**

Do not exceed the stated dose or duration of treatment.

Do not administer other NSAIDs concurrently or within 24 hours of each other.

Avoid intra-arterial injection.

Avoid use in dehydrated, hypovolaemic or hypotensive animals as there is a potential risk of increased renal toxicity.

Do not use in animals suffering from cardiac, hepatic or renal disease, where there is the possibility of gastro-intestinal ulceration or bleeding, or where there is evidence of a blood dyscrasia or hypersensitivity to the veterinary medicinal product.

## **6. Special warnings**

### Special precautions for safe use in the target species:

Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs to produce an increase in non-bound pharmacologically active concentrations, which can lead to toxic effects.

Use in any animal less than 6 weeks of age or in aged animals may involve additional risk. If such use cannot be avoided animals may require a reduced dosage and careful clinical management.

It is preferable that flunixin is not administered to animals undergoing general anaesthesia until fully recovered.

NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infections, appropriate concurrent antimicrobial therapy should be instigated.

Concurrent administration of potentially nephrotoxic drugs should be avoided.

For animal treatment only.

### Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Avoid eye contact and direct contact with skin.

To avoid possible sensitisation reactions, avoid contact with skin. Personal protective equipment consisting of gloves should be worn when handling the veterinary medicinal product.

Wash hands after use.

In the case of accidental contact with eyes, rinse immediately with plenty of water and seek medical advice.

The veterinary medicinal product may cause reactions in sensitive individuals. People with known hypersensitivity for non-steroidal anti-inflammatory products should avoid contact with the veterinary medicinal product. Reactions may be serious. In case of hypersensitivity reactions seek medical advice and show the package leaflet or the label to the physician.

Take care to avoid accidental self-injection.

### Pregnancy and lactation:

Do not administer to mares. Studies to demonstrate safety in pregnant mares have not been conducted.

### Interaction with other medicinal products and other forms of interaction:

Do not mix the veterinary medicinal product with other medicaments prior to administration.

Monitor drug compatibility closely where adjunctive therapy is required.  
Due to their common mode of action, flunixin may potentiate and be potentiated by other NSAIDs which act by interfering with prostaglandin synthesis.

Overdose:

Do not exceed the recommended dose or treat animals for more than 5 consecutive days. Tolerance trials in cattle and horses confirmed excellent tolerance to the veterinary medicinal product at twice the recommended dose.

Major incompatibilities:

None known.

## 7. Adverse events

Horses and Cattle:

Undetermined frequency (Cannot be estimated from the available data):	Gastrointestinal irritation <sup>1</sup> Gastrointestinal ulceration <sup>2</sup>
---	--

<sup>1</sup>Prolonged use of NSAIDs, including flunixin.

<sup>2</sup>Prolonged use of NSAIDs, including flunixin, in severe cases.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system at:

Website: <https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine>

e-mail: [adverse.events@vmd.gov.uk](mailto:adverse.events@vmd.gov.uk)

## 8. Dosage for each species, routes and method of administration

Intravenous injection.

Cattle:

The recommended dose is 2 ml of the veterinary medicinal product per 45 kg bodyweight (equivalent to 2.2 mg flunixin per kg) injected intravenously and repeated as necessary at 24 hour intervals for up to 5 consecutive days. The cause of the acute inflammatory condition should be determined and treated with concomitant therapy.

Horses:

For use in equine musculoskeletal disorders the recommended dose is 1 ml of the veterinary medicinal product per 45 kg bodyweight (equivalent to 1.1 mg flunixin per kg) injected intravenously and repeated as necessary at 24 hour intervals for up to 5 consecutive days according to clinical response.

For use in equine colic, the recommended dose is 1 ml of the veterinary medicinal product per 45 kg bodyweight (equivalent to 1.1 mg flunixin per kg) injected

intravenously and repeated once or twice if signs of colic recur. The cause of colic should be determined and treated with concomitant therapy.

### **9. Advice on correct administration**

None.

### **10. Withdrawal periods**

Cattle:

Meat and offal: 8 days.

Milk: 12 hours.

Horses:

Not authorised for use in horses intended for human consumption.

### **11. Special storage precautions**

Keep out of the sight and reach of children.

Do not store above 25 °C.

Keep the container in the outer carton.

Following withdrawal of the first dose, use the product within 28 days.

When the container is broached (opened) for the first time, using the in-use shelf life which is specified on this package leaflet, the date on which any veterinary medicinal product remaining in the carton should be discarded should be worked out. This discard date should be written in the space provided.

### **12. Special precautions for disposal**

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

### **13. Classification of veterinary medicinal products**

Veterinary medicinal product subject to prescription.

### **14. MARKETING AUTHORISATION NUMBER AND PACK SIZES**

Vm 50146/4011

50 ml & 100 ml clear glass Type I Vial with rubber bromobutyl bung with aluminium overseal.

Pack sizes:

Cardboard box with 1 x 50 ml bottle.

Cardboard box with 1 x 100 ml bottle.

Not all pack sizes may be marketed.

### **15. PID LINK (Do not print heading)**

*[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]*

Find more product information by searching for the 'Product Information Database' on [www.gov.uk](http://www.gov.uk).

### **16. Contact details**

Marketing authorisation holder:

Bimeda Animal Health Limited  
2 / 3 / 4 Airton Close  
Tallaght  
Dublin 24  
D24 FH9V  
Ireland

Manufacturer responsible for batch release:

Labiana Life Sciences S.A.  
Calle Venus 26  
Can Parellada  
08228 Terrassa, Barcelona  
Spain

Local representatives and contact details to report suspected adverse reactions:

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder listed below.

Cross Vetpharm Group UK Limited (Trading as Bimeda)  
Unit 2, Bryn Cefni Industrial Park  
Llangefni, LL77 7XA  
United Kingdom  
Tel: 01248 725 400

### **17. Other information**

POM-V

*Gavin Hall*  
Approved: 19 May 2026